Health Affairs November 1, 2024
Katherine A. Clifford, A. Alex Levine, Daniel E. Enright, Peter J. Neumann, James D. Chambers

Abstract

The Inflation Reduction Act of 2022 requires that Medicare negotiate a Maximum Fair Price for selected small-molecule drugs nine years after their Food and Drug Administration (FDA) approval and thirteen years postapproval for selected biologics. The discrepancy between these time frames raises questions about the relative value of small-molecule drugs versus biologics. We compared the incremental quality-adjusted life-year (QALY) gains, incremental costs, and incremental cost-effectiveness ratios (ICERs) of small-molecule drugs and biologics approved by...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Insurance, Medicare, Pharma / Biotech
Related Articles:
How Digital Chemistry Will Improve Cross-Functional Collaboration In The Biopharma Industry
How Agencies Should Decide Which Costly Drugs To Target With Government March-In Rights
Biotech startups are built on venture capital. Track funding rounds here.
Kura Oncology Gets $330M to Kick Off Global Leukemia Drug Pact With Kyowa Kirin
What might a Trump administration mean for the Biosecure Act?

Share This Article